Registration Dossier

Toxicological information


Currently viewing:

Administrative data

Description of key information

There are a multitude of published studies, including both animal and epidemiological studies, that address the carcinogenicity of Cr(VI) substances. The literature is summarised in various peer reviewed publications, e. g., EU RAR 2005 and ATSDR, 2012.

Chromium(VI) causes lung tumours in humans and animals by the inhalation route and tumours of the gastrointestinal tract in animals by the oral route. These are both local, site-of-contact tumours – there is no evidence that Cr(VI) causes tumours elsewhere in the bo

Reference dose response relationships for the carcinogenicity of hexavalent chromium substances are documented in the ECHA publication "Application for authorisation: Establishing a reference dose response relationship for carcinogenicity of hexavalent chromium", Ref RAC/27/2013/06 Rev.1, dated 4 Dec 2013.

Key value for chemical safety assessment

Additional information

Justification for classification or non-classification

Dichromium tris(chromate) is classified as a Carcinogen Category 1B, H350 according to Regulation (EC) No 1272/2008. No studies are available for dichromium tris(chromate), however studies in rats and mice with another Cr (VI) salt (sodium dichromate) demonstrated clear evidence of carcinogenicity via the oral exposure route. Therefore, no change to the current classification is proposed.